» Articles » PMID: 24809970

Review and Analysis of Differing Regulatory Indications and Expert Panel Guidelines for the Treatment of Hyponatremia

Overview
Publisher Informa Healthcare
Date 2014 May 10
PMID 24809970
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Objective: As evidence grows about the management of hyponatremia, a number of different international and national recommendations/guidelines from professional organizations have recently been published that offer guidance on decision-making. However, they include several important differences that could confuse practising physicians. This article summarizes the key differences in guideline recommendations by various independent groups, taking the marketing authorizations granted by different regulatory agencies into account. It proposes a synthesis of implications for practising physicians as a practical method for resolving these differences as they relate to everyday clinical practice.

Methods: The authors reviewed all recent guidelines and consensus documents worldwide to assess differences and similarities. They also reviewed licensed indications for therapeutic agents in hyponatremia.

Results: The actual indications for the only pharmacological therapy approved across three continents for the treatment of hyponatremia--the vaptans--differ substantially around the world. The numerous treatment guidelines published to date also fail to achieve agreement on hyponatremia management. The possible reasons for these differences are explored in this paper. The authors emphasize the crucial role that clinical judgment must continue to play in decision-making about the management of hyponatremia in individual patients. Such judgments should take into account appropriate appraisals of evidence by authoritative experts in the field, as well as the decisions of regulatory agencies that have based their approvals on a critical review of the efficacy and safety data for approved treatments for hyponatremia.

Conclusion: It is clinical judgment rather than guidelines that should dictate the ultimate choices physicians make for their patients, not only in hyponatremia, but in all aspects of medicine.

Citing Articles

Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct.

Khan S, Raghuram V, Chen L, Chou C, Yang C, Khundmiri S Am J Physiol Renal Physiol. 2023; 326(1):F57-F68.

PMID: 37916285 PMC: 10812694. DOI: 10.1152/ajprenal.00124.2023.


Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD).

Tzoulis P, Kaltsas G, Baldeweg S, Bouloux P, Grossman A Ther Adv Endocrinol Metab. 2023; 14:20420188231173327.

PMID: 37214762 PMC: 10192810. DOI: 10.1177/20420188231173327.


Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.

Warren A, Grossmann M, Christ-Crain M, Russell N Endocr Rev. 2023; 44(5):819-861.

PMID: 36974717 PMC: 10502587. DOI: 10.1210/endrev/bnad010.


Successful Treatment with Percutaneous Balloon Kyphoplasty for Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated with Vertebral Compression Fracture: A Case Report.

Izumida T, Sangen R, Usuda D, Kasamaki Y Am J Case Rep. 2021; 22:e928055.

PMID: 33661857 PMC: 7942206. DOI: 10.12659/AJCR.928055.


Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.

Pose-Reino A, de la Vega I, de Jong-Laird A, Kabra M, Lindner U Adv Ther. 2020; 38(2):1055-1067.

PMID: 33306187 DOI: 10.1007/s12325-020-01560-2.